Loading...
No images? Click here Tuesday, 23 November 2021 MEDIA ADVISORY 23 November 2021, Geneva | WHO today issued updated guidelines on the management of multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C). MIS-C is a rare but serious condition where children with COVID-19 develop inflammation affecting different organs of the body. Children with this condition need specialized care, and may need to be admitted to intensive care. Although MIS-C is a serious condition, with the right medical care, children with this condition recover. WHO’s updated guidelines recommend the use of corticosteroids in hospitalized children (aged 0-18 years) with this condition, in addition to supportive treatment and care. This recommendation comes following the availability of three observational studies, pooling data from 885 patients in total. WHO first described this condition in May 2020, and provided a preliminary clinical definition. Overall, children remain at a low of risk of developing severe or critical COVID-19, but similar to adults, certain underlying conditions make children more susceptible to severe disease. The most commonly reported of these conditions are obesity, chronic lung disease (including asthma), cardiovascular disease and immunosuppression. Guidance is available here Note: WHO has updated its webpage on COVID-19 therapeutics. On this page, you can find: - Information on COVID-19 therapeutics under assessment by WHO and current timelines for the development of clinical practice guidelines. - The most recent WHO guideline for therapeutics to treat COVID-19 and associated online interactive publication platform. - Open-access journal publications for the current therapeutic recommendations. - Resources and tools for health care workers to support prescribing and administering therapeutics and monitoring patients. - Resources for patients, caregivers and families. Media contacts: You are receiving this NO-REPLY email because you are included on a WHO mail list.
|
Loading...
Loading...